Differentiated thyroid cancer follow-up
thyroid Ca · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Long-term surveillance of papillary and follicular thyroid cancer after surgery, using thyroglobulin, neck ultrasound and risk-adapted TSH suppression. Most patients have excellent prognosis with dynamic risk stratification.
Red flags
- Rising thyroglobulin trend
- New suspicious cervical lymphadenopathy
- Hoarseness or dysphagia (local recurrence)
- Rapidly enlarging mass (anaplastic transformation)
- Symptomatic distant metastases
Assessment
Differential diagnosis
- Benign thyroid nodule
- Medullary thyroid cancer
- Anaplastic thyroid cancer
- Thyroid lymphoma
- Metastasis to thyroid
Investigations
- Serum thyroglobulin and anti-thyroglobulin antibodies
- Neck ultrasound for nodal/bed recurrence
- TSH and free T4 to guide suppression
- Stimulated thyroglobulin or diagnostic radioiodine scan in selected cases
- Cross-sectional imaging for suspected distant disease
Management
- Stratify initial risk (low/intermediate/high) using ATA criteria
- Set TSH target by risk: suppressed <0.1 (high), 0.1-0.5 (intermediate), 0.5-2.0 mU/L (low-risk, excellent response)
- Measure thyroglobulin on levothyroxine with antibody status at each review
- Perform neck ultrasound periodically for structural recurrence
- Reassess as dynamic response (excellent, indeterminate, biochemical, structural incomplete)
- De-escalate TSH suppression once excellent response achieved
- Investigate rising thyroglobulin or suspicious nodes with imaging and biopsy
- Consider further surgery or radioiodine for structural recurrence
- Use targeted kinase inhibitors for progressive radioiodine-refractory disease
Drugs & doses
Levothyroxine titrated to risk-based TSH target
Radioactive iodine (I-131) for remnant ablation/recurrence per protocol
Lenvatinib or sorafenib for radioiodine-refractory progressive disease
Selpercatinib/other targeted agents for actionable mutations
Disposition
Lifelong endocrine/oncology follow-up with multidisciplinary review; refer progressive or refractory disease for systemic targeted therapy.
Complications & pitfalls
- Local/nodal recurrence
- Distant metastasis (lung, bone)
- Over-suppression causing atrial fibrillation/osteoporosis
- Radioiodine-related sialadenitis
- Radioiodine-refractory progression
Exam pearls
- Thyroglobulin is the key tumour marker but is uninterpretable when antibodies are present
- Dynamic risk restratification lets most low-risk patients relax TSH suppression over time
- Neck ultrasound detects most recurrences, which are usually nodal
- Balance suppression benefit against cardiac and skeletal harm, especially in the elderly
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.